Beta blockers in heart failure: Issues in the management of individual patients

Heart Failure Reviews

Volumn 4, Issue 1, 1999, Pages 65-78

  Metra, Marco ^a   Nodari, Savina ^a   D'Aloia, Antonio ^a   Cagnazzi, Elena ^a   Fiorina, Claudia ^a   Verde, Simone ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; PROPRANOLOL;

ADRENERGIC STIMULATION; ALPHA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; PATHOPHYSIOLOGY; REVIEW;

EID: 0032864349     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009807918615     Document Type: Review

References (110)

1. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure, Circulation 1997;95:169-175.
2. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C, Kubo SH, Rudin-Toretsky E, Yusuf S, for the SOLVD Investigators Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729.
3. Levine TB, Francis GS, Goldsmith SR, Simon A, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982;49:1659-1666.
4. Francis GS, Goldsmith SR, Cohn JN. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982;104:725-731.
5. Viquerat CE, Daly P, Swedberg K. Endogenous catecholamine levels in congestive heart failure: Relation to severity of hemodynamic abnormality. Am J Med 1985;78:455-460.
6. Packer M. The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
7. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71:3C-11C.
8. Bristow MR. The adrenergic nervous system in heart failure. New Engl J Med 1984;311:850-851.
9. Fowler MB, Bristow MR. Rationale for beta adrenergic blocking drugs in cardiomyopathy. Am J Cardiol 1985;55: D120-D124.
10. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L-40L.
11. Benedict CR, Shelton B, Johnstone DE, Francis GS, Greenberg B, Konstam M, Probstfield JL, Yusuf S, for the SOLVD Investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-697.
12. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon A. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl JMed 1984;311:819-823.
13. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87(Suppl VI):VI-40-VI-48.
14. Kaye DM, Lefkovitz J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-1263.
15. Port HD, Weinberger JD, Bisognano OA, Knudson TJ, Bohlmeyer TJ, Pende A, Bristow MR. Echocardiographic and histopathological characterization of young and old transgenic mice over-expressing the human beta1-adrenergic receptor. J Am Coll Cardiol 1998;31(Suppl A):177A.
16. sa overexpression. Circ Res 1996;78:517-524.
17. sa overexpression. Am J Physiol 1997;41:H585-H589.
18. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997;9:2189-2195.
19. Eichorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 1996;94: 2285-2296.
20. Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996;17:1629-1639.
21. Waagstein F. Efficacy of beta blockers in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Am J Cardiol 1997;80:45J-49J.
22. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and idgoxin on the progression of left ventricular dysfunction and dilation in digs with reduced ejection fraction. Circulation 1994;89:2852-2859.
23. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994;24:1762-1768.
24. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: Promising or proved? J Am Coll Cardiol 1994; 23:814-821.
25. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
26. Eichorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux L, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
27. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose response of chronic beta blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-1642.
28. Metra M, Nardi M, Giubbini R, Dei Gas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
29. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
30. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
31. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-1161.
32. Packer M, Colucci WS, Sackner-Bernstein J, Liang C, Goldscher D, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial. Circulation 1996;94:2793-2799.
33. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806.
34. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
35. Metra M, Nodari S, Raccagni D, Garbellini M, Boldi E, Grigolato M, Rosselli F, Zanini R, Dei Cas L. Effects of long-term carvedilol admionistration in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1996;29 (Suppl A):326A.
36. Lowes BD, Gill EA, Rodriguez-Larrain J, Abraham WT, Bristow MR, Gilbert EM. Carvedilol is associated with a reversal of remodeling in chronic heart failure. Circulation 1996;94(Suppl I):I-407.
37. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, on behalf of the Australia New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29: 1060-1066.
38. Lechat PP, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
39. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
40. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349-1355.
41. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised placebo-controlled trial of carve dilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-380.
42. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
43. st Scientific Sessions of the American Heart Association, Dallas 8-11 November 1998.
44. Packer M, Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol 1997;80: 46L-54L.
45. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A. Long term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563.
46. Frishman WH. Carvedilol. New Engl J Med 1998;339: 1759-1765.
47. Feuerstein G, Yue T-L, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Progr Cardiovasc Dis 1998;41(Suppl 1):17-24.
48. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79: 483-490.
49. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825.
50. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Butcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17(Suppl B):8-16.
51. Metra M, Nodari S, D'Aloia A, Madureri A, Rosselli F, Bontempi L, Zanini R, Dei Gas L. Effects of neurohumoral antagonism on symptoms and quality of life in heart failure. Eur Heart J 1998;19(Suppl B):B25-B35.
52. 2-adrenergic receptors hasten relaxation and mediates phosphorilation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients terminal heart failure. Circulation 1999;99:65-72.
53. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303.
54. 2-adrenoceptors in human atrial myocardium. Circ Res 1990;66:1610-1623.
55. Boudreau G, Peronnet F, De Champlain J, Nadeau R. Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in the dogs. Am J Physiol 1993; 265:H205-H211.
56. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker-vasodilator therapy improves cardiac function in idiopathic dilated ??
57. Newton GE, Parker JD. Acute effects of beta1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996;94:353-358.
58. 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96: 1914-1922.
59. Reid JL, White KF, Struthers AD. Epinephrine induced hypokaliemia: The role of beta-adrenoceptors. Am J Cardiol 1986;57:23F-27F.
60. Leier CV, Dei Gas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokaliemia, and hypomagnesemia. Am Heart J 1994;128:564-574.
61. Yusuf S, Peto R, Lewis J, Collins R, Sleigh P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
62. Eichorn EE, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997;79;794-798.
63. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, Hjalmarson A, Sonneblick EH. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials. Eur Heart J 1992; 13:28-32.
64. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988;1:921-923.
65. Leier CV, Binkley PF, Cody RJ. Alpha-adrenergic component of the sympathetic nervous system in congestive heart failure. Circulation 1990;82(Suppl I):I-68-I-76.
66. Hesse IF, Johns EJ. The role of alpha-adrenoceptors in the regulation of renal tubular reabsorption and renin secretion in the rabbit. Br J Pharmacol 1985;84:715-724.
67. Smyth DD, Unemura S, Pettinger WA. Renal nerve stimulation causes alpha1-adrenoceptor mediated sodium retention but not alpha2-adrenoceptor antagonism of vasopressin. Circ Res 1985;57:304-311.
68. Abraham WT, Tsvetkova T, Lowes BD, Ferguson DA, Gilbert EM, Bristow MR. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 1998;98(Suppl I):I-378-I-379.
69. 1 adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. Circulation 1991;84:1732-1740.
70. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation 1991;83: 13-25.
71. Simpson P, McGrath A. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1-adrenergic response. J Clin Invest 1983;72:732-737.
72. Yue T-L, Wang X, Romanic AM, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/ reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998;82:166-174.
73. Metra M, Nodari S, Garbellini M, Boldi E, Zanini R, Dei Cas L. Comparative effects of metoprolol and carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. Circulation 1997;96:I-577-I-578.
74. Di Lenarda A, Salvatore L, Gregori D, Sinagra G, Sabbadini G, Longaro F, Bernobich E, Klugman S, Camerini F. Effects of carvedilol on LV function and remodeling in patients with dilated cardiomyopathy with persistent LV dysfunction despite optimal conventional therapy. J Am Coll Cardiol 1998;31(Suppl A):189A.
75. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-565.
76. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
77. Poole-Wilson PA, Swedberg K, Remme WJ, Cleland J, Camerini F, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Helmers C, Pfarr E, Skene A, Ehmer B, Cabri P. A multicentre randomised double-blind study to compare the effect on mortality and morbidity over 24-44 months of carvedilol and metoprolol in patients with moderate or severe congestive heart failure (NYHA II-IV) - COMET (Abstract). Heart Failure 1997;41.
78. Krumholz HM. Beta-blockers for mild to moderate heart failure. Lancet 1999;353:2-3.
79. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-2464.
80. Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B. Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice. J Am Coll Cardiol 1995;25: 1327-1332.
81. Ramachandian S, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: An epide miological perspective. J Am Coll Cardiol 1995;26:1565-1574.
82. Senni M, Trobouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community. A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-2289.
83. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR. Beta-blockade with bucindolol in heart failure due to ischemic vs idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
84. 2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J Am Coll Cardiol 1989;14:323-331.
85. Hamawaki M, DeFreyte G, Carabello BA. Beta-blockade must be added to ACE inhibition to improve hemodynamics and contractile function in experimental mitral regurgitation. J Am Coll Cardiol 1998;31(Suppl A):205A.
86. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997;80:9J-14J.
87. Gilbert EM, Colucci WS, Fowler MB, Lukas MA, Young ST, Hirshberger R, Adams K, de Marchens E, Kreuger S, Karlsburg R, Liang C-S, for the US Carvedilol Heart Failure Study Group. Carvedilol without ACE inhibition in the treatment of patients with moderate to severe heart failure. Circulation 1996;94(Suppl I):I-663.
88. Eichorn EJ, Lukas MA, Wu B, Shusterman N, for the US Carvedilol Heart Failure Study Group. Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity. Eur Heart J 1998;19(Abstract suppl):301.
89. Krum H, Shusterman N, MacMahon S, Sharpe N. Safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Circulation 1996;96(Suppl I):I-578.
90. MacDonald PS, Keogh AM, Aboyoun C, Amor R, Lund M. The impact of concurrent amiodarone therapy on the response to carvedilol in heart failure. Circulation 1996;96 (suppl I):I-578.
91. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? N Engl J Med 1997;336:575-576.
92. Cleland JGF, McGowan J, Cowburn PJ. Beta-blockers for chronic heart failure: From prejudice to enlightenment. J Cardiovasc Pharmacol 1998;32(Suppl I):S52-S60.
93. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Robertson AD, Krueger S. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic cardiomyopathy. Circulation 1996;94:1-664.
94. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
95. Norwegian Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;2:823-827.
96. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
97. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled randomized trial. Circulation 1997;96:183-191.
98. Cohn JN, Fowler MB, Bristow MR, Colucci W, Bristow MR, Packer M. Safety and efficacy of carvedilol in severe heart failure. J Cardiac Failure 1997;3:173-179.
99. Eichorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B. Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 1995;25:154-162.
100. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel J-P, Mallet A, on behalf of the CIBIS Investigators. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997;96:2197-2205.
101. Packer M, Colucci WS, Cohn JN, Bristow MR, Fowler MB, Gilbert EM, Hu JZ, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. Relationship between long-term changes in left ventricular function and clinical outcome in patients with chronic heart failure treated with carvedilol. J Am Coll Cardiol 1997;29(suppl A):64A.
102. Packer M. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiavasc Dis 1998;41(Suppl 1):39-52.
103. Epstein SE, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;75:20-27.
104. Stephens SA. Unwanted effects of propranolol. Am J Cardiol 1966;18:463-472.
105. Fowler MB, Colucci WS, Bristow MR, Packer M, Gilbert EM, Cohn JN, wu B, Hu JZ, Lukas MA, Kubo S, Hershberger R, Gottlieb S, Pina I, for the US Carvedilol Heart Failure Study Group. Tolerability of carvedilol initiation in heart failure patients.
106. The task force of the Working group on heart failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997;18:736-753.
107. Sackner-Bernstein JD. Use of carvedilol in chronic heart failure: Challenges in therapeutic management. Prog Cardiovasc Dis 1998;41(Suppl 1):53-58.
108. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-1340.
109. Sackner-Bernstein JD, Krum H, Goldsmith R, Kukin ML, Medina N, Yushak M, Packer M. Should worsening hear failure early after initiation of beta-blocker therapy for chrome heart failure preclude long-term treatment? Circulation 1995;92(Abstract suppl):395.
110. Lowes BD, Abraham WT, Dutcher DR, Roden RL, Crisman TS, Minobe W, Port DJ, Larrabee P, Gilbert EM, Bristow MR. Comparative anti-adrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled trial. Circulation 1996;94(suppl I):I-664.